-
Published 10/28/2025
Wixner J, Conceição I, Berk JL, Adams D, Polydefkis MJ, Attarian S, Gillmore JD, Dyck PJB, Chen J, Kwoh TJ, Nåtman J, Zhou W, Cruz MW. Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2025 Oct 28; 1-5. PMID: 41147681.
-
Published 8/12/2025
Maurer MS, Berk JL, Damy T, Sheikh FH, González-Costello J, Morbach C, Delgado D, Bondue A, Azevedo O, Poulsen SH, Jankowska EA, Yang L, Bender S, Eraly SA, Jay PY, Vest J, Fontana M. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025 Aug 12; 86(6):459-475. PMID: 40769675.
-
Published 6/23/2025
Berk JL, Lairez O, Schwartzmann P, Bender S, White MT, Jay PY, Danese D, Witteles R. Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B. JACC Adv. 2025 Aug; 4(8):101876. PMID: 40555140.
-
Published 3/31/2025
Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2025 Aug; 18(8):e012112. PMID: 40160093.
-
Published 3/1/2025
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 01; 82(3):228-236. PMID: 39804640.